Join Nasal-Phyto Company News Technical Support 中文

纳菲制药

Nasal-Phyto

Join Nasal-Phyto Technical Support Chinese

Technical Research

As an innovator of transformative therapies and drug delivery in the upper nasal cavity, we seek to use our expertise in drug delivery in the upper nasal cavity to devote ourselves to the development of a series of innovative drugs and improved new drugs for neurological diseases to meet the disease of the central nervous system. Patient needs. We seek partnerships with those who share our expertise in the development and commercialization of CNS drugs.

The invention discloses a carrier-free nasal nanometer preparation brain targeted delivery system modified by chitooligosaccharide and a preparation method thereof.The preparation method of the brain targeted delivery system of the nasal nanometer preparation is also provided. The invention has a simple preparation method, which can improve the hydrophobicity, reduce toxicity and enhance the neuroprotective effect of small-molecule drugs. The preparation method of the brain targeted delivery system of the nasal nanometer preparation is also provided.There was no carrier, no biodegradation problem and no accumulation toxicity, the drug loading rate was up to more than 25%, and the drug was well absorbed through the membrane after chitosan oligosaccharide modification, and the drug was delivered into the brain with high targeting.

Published Articles and Poster Presentations

To learn more about our innovative technology, we recommend reading the following:

Public announcement on the transfer of patent application right of "a carrier-free brain targeted delivery system for nasal nanometer preparation modified by chitooligosaccharide and its preparation method"

First new mechanism for antidepressants in 30 years! Johnson & Johnson Spravato nasal spray has filed for new indications in the United States

Severe depression new drugs on the market! FDA approves new nasal sprays that work quickly

Parkinson's drug! The first inhaled levodopa product, Inbrija, has been launched in the us, and a new drug to treat off-season (OFF) symptoms for 340 million patients worldwide is expected to be launched next year

First new drug in 20 years! Nayzilam, a new epilepsy drug, was approved by the FDA

Human sciences FDA approves first generic nasal spray for opioid overdose

Scientific Support

Shi xuemin, Academician of Chinese Academy of Engineering and master of Chinese medicine

Yi-Ling Wu,Academician of Chinese Academy of Engineering、Yi-Ling pharmacy chairman

Li Dapeng,Academician of Chinese Academy of Engineering、Zhejiang kangte pharmaceutical co. LTD

Xiao-bo Sun，Director, institute of medicinal plants, Chinese academy of medical sciences

Xianzheng Zhang, Distinguished professor of changjiang scholars、National outstanding youth

Jian-Gang Shen , Professor, faculty of medicine, university of Hong Kong、Vice President, school of traditional Chinese medicine

Prof.Omid Farokhzad，Harvard University

Prof.Jinjun Shi，Harvard University